ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "juvenile idiopathic arthritis (JIA) and tumor necrosis factor (TNF)"

  • Abstract Number: 2166 • 2013 ACR/ARHP Annual Meeting

    Infection Risk With Tumor Necrosis Factor Inhibitor Use In Polyarticular Juvenile Idiopathic Arthritis

    Caroline Y Chang1, Rika Meyer2 and Katherine AB Marzan1, 1Division of Rheumatology, Children's Hospital Los Angeles, Los Angeles, CA, 2Children's Hospital Los Angeles, Los Angeles, CA

    Background/Purpose: Tumor Necrosis Factor inhibitors (TNFi) are extremely effective in treating Juvenile Idiopathic Arthritis (JIA).  However, TNF-α is critical in immune function, raising concerns of…
  • Abstract Number: 794 • 2013 ACR/ARHP Annual Meeting

    Recent Trends In Medication Usage for the Treatment of Juvenile Idiopathic Arthritis and the Influence of TNF Inhibitors

    Melissa L. Mannion1, Fenglong Xie2, Jeffrey R. Curtis3 and Timothy Beukelman1, 1Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 2Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, 3Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: The pharmacologic management of JIA has changed dramatically with the advent of tumor necrosis factor inhibitors (TNFi), but the impact of TNFi on medication…
  • Abstract Number: 282 • 2013 ACR/ARHP Annual Meeting

    Rates Of Flare-Free Survival In Juvenile Idiopathic Arthritis When Tapering Individual Components Of Tumor Necrosis Factor Inhibitor and Methotrexate Combination Therapy

    Caroline Y Chang1, Rika Meyer2 and Andreas Reiff1, 1Division of Rheumatology, Children's Hospital Los Angeles, Los Angeles, CA, 2Children's Hospital Los Angeles, Los Angeles, CA

    Background/Purpose: Combination therapy of tumor necrosis factor inhibitors (TNFi) and methotrexate (MTX) is a well-established treatment that has dramatically changed outcomes in Juvenile Idiopathic Arthritis…
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology